^
    Back
    Association details:
    Biomarker:PTEN deletion
    Cancer:Gastric Cancer
    Drug:AZD8186 (PI3Kβ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    AZD8186 and Paclitaxel in Advanced Gastric Cancer

    Excerpt:
    ...Phase 2b: Subjects with histologically confirmed locally advanced or metastatic gastric cancer that have progressed after treatment with first-line fluoropyrimidine-based chemotherapy, with PTEN loss by immunohistochemistry (IHC), PTEN gene abnormality (PTEN gene deletion or loss of function mutation) or Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta(PIK3CB) gene abnormality (amplification or gain of function mutation) identified by next generation sequencing (NGS)....
    Trial ID:
    NCT04001569
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    The Oncologist
    Title:

    AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)

    Published date:
    04/10/2023
    Excerpt:
    In phase Ib, both MTD and RP2D were determined at paclitaxel 80 mg/m2 and AZD8186 120 mg BID. In phase II, 18 patients were enrolled [PTEN loss (n = 18) and PIK3CB mutation (n = 1)]. The 4-month PFS rate was 18.8% (3 of 16 evaluable patients)...The combination of AZD8186 and paclitaxel was well tolerated...clinical efficacy was observed.
    Secondary therapy:
    paclitaxel
    DOI:
    10.1093/oncolo/oyad059
    Trial ID:
    NCT04001569